GlassScriptPhysician profile
Tilak Sunil Kalaria
NPI 1427400209
$3,505.44
in general payments reported to CMS, 2019-2025
24 companies · $279 in 2025
The $279 reported for 2025 was more than what 82% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $179 · 2020: $382 · 2021: $724 · 2022: $760 · 2023: $851 · 2024: $330 · 2025: $279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,459.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,085.13 | 2021-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $503.43 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $365.91 | 2019-2025 | Xifaxan |
| Abbvie INC. | $234.68 | 2021-2023 | |
| Alexion Pharmaceuticals, INC. | $201.50 | 2019-2025 | Ultomiris |
| Astrazeneca Pharmaceuticals LP | $176.09 | 2020-2024 | Farxiga |
| Amgen INC. | $145.85 | 2022-2025 | |
| Allergan, INC. | $116.91 | 2019-2020 | |
| Inari Medical, INC. | $109.07 | 2022-2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Melinta Therapeutics, LLC | $89.12 | 2021-2024 | Rezzayo, Orbactiv, Kimyrsa |
| E.R. Squibb & Sons, L.L.C. | $73.32 | 2021-2022 | |
| Pfizer INC. | $57.17 | 2021-2022 | |
| Smith+Nephew, INC. | $51.52 | 2022 | |
| Ferring Pharmaceuticals INC. | $36.68 | 2023-2024 | Rebyota |
| Scpharmaceuticals INC. | $33.27 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $32.76 | 2023 | Watchman Access System |
| Bioxcel Therapeutics, INC. | $32.67 | 2023 | Igalmi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.90 | 2023 | Jardiance |
| Ucb, INC. | $24.87 | 2019 | |
| Insmed, INC. | $24.65 | 2025 | Arikayce |
| Vifor Pharma, INC. | $24.59 | 2019 | |
| Argenx US, INC. | $22.59 | 2023 | Vyvgart |
| Gilead Sciences, INC. | $16.04 | 2025 | Veklury |
| Tetraphase Pharmaceuticals, INC. | $15.72 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tilak Kalaria listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.